The Limited Times

Now you can see non-English news...

Better booster vaccination: Moderna's new combination booster convinces in the study

2022-04-20T18:13:56.361Z


Better booster vaccination: Moderna's new combination booster convinces in the study Created: 04/20/2022, 20:01 By: Christoph Gschossmann Every vaccination must be included in the vaccination card: the new booster vaccination from Moderna is said to be more effective against Omicron. © Felix Schlikis/imago The booster vaccination could soon be replaced by a better one: the new vaccination from


Better booster vaccination: Moderna's new combination booster convinces in the study

Created: 04/20/2022, 20:01

By: Christoph Gschossmann

Every vaccination must be included in the vaccination card: the new booster vaccination from Moderna is said to be more effective against Omicron.

© Felix Schlikis/imago

The booster vaccination could soon be replaced by a better one: the new vaccination from Moderna was convincing in a study.

Munich – The booster against the corona virus should become even more effective: According to a new study, Moderna’s combination booster should protect against omicron better than the previous booster vaccination.

According to the STIKO recommendation, “Comirnaty” from Biontech/Pfizer and “Spikevax” from Moderna are currently being vaccinated in boosters in Germany.

The bivalent vaccine targets two types of pathogens.

Bivalent vaccines immunize against two pathogens or two types of pathogens.

The vaccine targets both the beta variant and the original coronavirus.

As announced by Moderna, the vaccine shows a better immune response against a number of virus variants.

The US pharmaceutical company said the new vaccine had higher neutralizing antibody titers against the omicron variant than the booster shot of the vaccine currently in use.

Moderna is also testing another bivalent vaccine

Moderna's Jacqueline Miller said her company has no plans to seek approval for the bivalent vaccine, including the beta variant.

However, the data would be sent to the US Food and Drug Administration (FDA) to lay the groundwork for a future bivalent vaccine candidate targeting Omicron.

300 subjects took part in the US study.

Moderna has also started testing another bivalent vaccine that combines an omicron-specific vaccine with its original.

Miller: “To be prepared for the fall, we had to start production at risk.

Our belief is that, based on the data we have already observed, the bivalent offers the best hope for longer and more durable protection.”

(cg)

Read all news about the pandemic in the current ticker on Corona News in Germany.

Source: merkur

All news articles on 2022-04-20

You may like

Trends 24h

Latest

© Communities 2019 - Privacy

The information on this site is from external sources that are not under our control.
The inclusion of any links does not necessarily imply a recommendation or endorse the views expressed within them.